STVN
Stevanato Group S.p.A.
Next earnings Aug 3, 2026 (before open) · consensus $0.13 EPS, $305M rev
$17.84
▼ -2.99%$17.84▼ -23.12%
over 1Y
L $13.38EODHDH $27.85
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-3.0%
1W-3.0%
1M-0.9%
3M+33.3%
YTD-13.0%
1Y-23.1%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 17 analysts
Buy
Italian drug-containment maker (ADR) with no SEC XBRL fundamentals beyond a share count — not analyzable at $17.54.
Stevanato Group is an Italian manufacturer of drug-containment and delivery systems (vials, syringes, cartridges) and analytical/inspection equipment for pharma and biotech. It files with the SEC as a foreign private issuer on Form 6-K, and the only structured datapoint available here is a share count of 303M (FY2025) — no revenue, earnings, margins, cash flow, or balance sheet. With no financial statements, there is no basis to evaluate the business or to relate the $17.54 quote to underlying value.
Financials · annual, by fiscal year
No income data filed.
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$5.40B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗4Period ending 2026-06-122026-06-26open ↗4Period ending 2026-06-122026-06-26open ↗4Period ending 2026-06-122026-06-26open ↗4Period ending 2026-06-122026-06-26open ↗4Period ending 2026-06-122026-06-26open ↗4Period ending 2026-06-122026-06-26open ↗4Period ending 2026-06-092026-06-26open ↗4Period ending 2026-06-122026-06-26open ↗4Period ending 2026-06-122026-06-26open ↗6-KPeriod ending 2026-06-052026-06-05open ↗SDFiling2026-05-29open ↗6-KPeriod ending 2026-05-152026-05-15open ↗
Frequently asked
- Is Stevanato Group S.p.A. (STVN) a buy?
- STVN currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Italian drug-containment maker (ADR) with no SEC XBRL fundamentals beyond a share count — not analyzable at $17.54.
Sources: SEC EDGAR (CIK 0001849853, latest 4 filed 2026-06-26) · EODHD · analysis by claude-code · as of 6/21/2026, 9:00:25 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.